Updates are available Correction dated 2021-11-20
Click to view Correction: https://doi.org/10.1186/s12931-021-01894-7
-
Authors
Singh, Dave http://orcid.org/0000-0001-8918-7075
Criner, Gerard J.
Naya, Ian
Jones, Paul W.
Tombs, Lee
Lipson, David A.
Han, MeiLan K.
-
Funding
Funding for this research was provided by:
GSK (Not Applicable)
- License Information
-
More Information
Article History
Received: 26 November 2019
Accepted: 5 May 2020
First Online: 2 June 2020
Change Date: 20 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12931-021-01894-7
Ethics approval and consent to participate
: Not applicable.
: Dave Singh has received personal fees from GSK, Cipla, Genentech and Peptinnovate, and personal fees and grant support from AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Theravance and Verona. Gerard Criner has received personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, CSA Medical, Eolo, GSK, HGE Technologies, Novartis, Nuvaira, Olympus, Pulmonx, Verona and NGM Bio. MeiLan K Han has received personal fees from Boehringer Ingelheim, and AstraZeneca and research support from Novartis and Sunovion. Ian Naya was an employee of GlaxoSmithKline (GSK) at the time of writing this review and holds GSK stocks/shares, and is a contractor on assignment for AstraZeneca. Paul W Jones and David A Lipson are employees of GSK and hold GSK stocks/shares. Lee Tombs is a contingent worker on assignment at GSK.
